## PTO/SB/08 Equivalent 10/828,795 Application No. DISCLOSURE Filing Date April 21, 2004 First Named Inventor Weber et al. STATEMENT BY APPLICANT Art Unit 1614 Examiner Sharon Brooks-(Multiple sheets used when necessary) SHEET 1 OF 2 Attorney Docket No. OREX.001A

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
3	1	5,512,593	04/30/96	Dante		
3	2	5,817,665	10/06/98	Dante	514/282	
4	3	5,856,332	01/05/99	Dante		
3	4	5,958,962	09/28/99	Cook		
Ry	5	6,034,091	03/07/00	Dante		
2	6	2004/0122033	06/24/04	Nargund et al.		

or (in CADITAL LETTERS) title of the orticle (when appropriate) title of the
or (in CAPITAL LETTERS), title of the article (when appropriate), title of the population, catalog, etc.), date, page(s), volume-issue aber(s), publisher, city and/or country where published.
oning of the mouse obese gene and its humane homologue," Nature
Disord. 28:325-332 (2000).
nucleus as a conduit for diverse signals relevant to energy homeostasis,"Int'l 63-S67 (2001).
feed: Homeostatic and hedonic control of eating," Neuron, 36:199-211
ng science of body weight regulation and its impact on obesity treatment," <i>J.</i> 70 (2003).
Chem., 35:1927 (1992).
, 46:10 (2003).
5, 33:350 (1999).
lelv. Chim. Acta, 77:999 (1994).
per. Therapeutics, 235:846-850 (1985).
cal Res., 6:266-271 (1985).
Chem., 23:674-676 (1980).

		9////
Examiner Signature	Date Date	Considered 4/6/6/
- Com	000	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application No.	10/828,795
INFORMATION DISCLOSURE	Filing Date	April 21, 2004
STATEMENT BY APPLICANT	First Named Inventor	Weber et al.
STATEMENT BY APPLICANT	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Sharon Brooks Nancy Zhany
SHEET 2 OF 2	Attorney Docket No.	OREX.001A

		NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ¹
N	19	Le Bourdonnec et al. J. Med. Chem., 43:2489-2492 (2000).	
ny	20	Sayre et al. J. Med. Chem., 27:1325 (1984).	
3	21	Erez et al. J. Med. Chem., 25:847-849 (1982).	
	22	Dechant et al. Drugs, 41:225-253 (1991).	
Ny Ny	23	Tamiz et al. J. Am. Chem. Soc., 122:5393-5394 (2000).	
ry	24	Tamiz et al. J. Med. Chem., 44:1615:1622 (2001).	
ry	25	Hussey et al. J. Am. Chem. Soc., 125:3692-3693 (2003).	
N	26	Portoghese et al. Life Sci., 31:1283-1286 (1982).	
ny	27	Portoghese et al. J. Med. Chem., 29:1855-1861 (1986).	
N	28	Stepinski et al. Internat. J. of Peptide & Protein Res., 38:588-592 (1991).	
N	29	Parr et al. J. Immunol., 169:856-864 (2002).	
13	30	Klok et al. Macromolecules, 35:746-759 (2002).	
By By	31	Portoghese et al. J. Med. Chem., 29:1650-1653 (1986).	
N	32	Sashiwa et al. Macromolecules, 33:6913 (2000).	
N	33	Ninan et al. Tetrahedron., 48:6709:16 (1992).	
N	34	Zeng et al. Tetrahedron Lett., 29:5123 (1988).	
14	35	Remington's Pharmaceutical Sciences. 18 <sup>th</sup> Edition; Easton, PA: Mack Publishing Co. (1990).	
3	36	Fingl et al. The Pharmacological Basis of Theraputics. Ch.1, pp 1. (1975).	

1787941 062405

Examiner Signature Meure	y the men	Date Considered	8/16	106
*F			Desur line th	arough citation if not

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08 Equivalent

## 10/828,795 Application No. INFORMATION DISCLOSURE **Filing Date** April 21, 2004 **Eckard Weber First Named Inventor** STATEMENT BY APPLICANT Art Unit 1614 Sharon Brooks Nancy Zhang O I P Aultiple sheets used when necessary) Examiner Attorney Docket No. OREX.001A SHEET 1 OF 1

SEP 0 2 2005 \$

	-44		
1300 m	ŔŽ	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т¹
N	1	Spigset, et al. Therapeutic Approaches to Bulimia Nervosa, Expert Opinion on Therapeutic Patents, Vol. 11, No. 3, 2001, Pages 463-477; XP002292382	
B	2	Islam, et al. Naltrexone, Serotonin Receptor Subtype Antagonists, and Carbohydrate Intake in Rats, Pharmacology Biochemistry and Behavior, Vol. 48, No. 1, 1994, pages 193-201; XP002292383	
B	3	Olszewski, et al. Evidence of Interactions Between Melanocortin and Opioid Systems in Regulation of Feeding, Neuroreort, Vol 12, No. 8, June 13, 2001, pages 1727-1730; XP009035026.	
N	4	Zhu, et al. <i>Pharmacologic Treatment of Easting Disorders, Canadian Journal of Psychiatry</i> , Vol 47 No. 3, April 3, 2002 pages 227-234; XP009035028	
N	5	Werneke, et al. Options for Pharmacological Management of Obesity in patients Treated with Atypical Antipsychotics, International Clinical Psychopharmacology, Vol 17 No. 4, 2002, pages 145-160; XP009035036	
N	6	Fuller et al., Fluoxetine: A Serotonergic Appetite Suppressant Drug, Drug Development Research, Vol. 17, No. 1, 1989, pages 1-15; XP009035038.	
	7	International Preliminary Examination Report PCT Application PCT/US2004/012393, mailed on June 29, 2005.	

1906871 083105

Examiner Signature Many Steam Date Considered 8/16/66

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.